Research Interest

1. Transition-Metal-Catalyzed C–H Functionalization for Heterocycle Synthesis/Modification

Our laboratory focuses on developing transition-metal-catalyzed C–H functionalization strategies to transform inert bonds into valuable functionalities. We explore catalytic systems that efficiently construct heterocycles and expand molecular frameworks, enabling access to structurally diverse scaffolds. Through systematic derivatization and late-stage diversification, we generate bioactive small-molecule libraries with potential therapeutic relevance.

2. Collaborative Translational Research for Small-Molecule Therapeutics

We work closely with domestic and international partners to accelerate early-stage drug discovery.

Our integrated discovery pipeline incorporates:

- Structure-based design supported by AI-based modeling, molecular docking, and in silico screening

- Hit identification using ligand-guided and target-informed strategies

- SAR-driven hit-to-lead and lead optimization through iterative synthesis

- Biochemical and cellular assays performed with collaborators in virology, oncology, and pharmacology

- In vivo efficacy studies through external research partners

Together, these efforts enable the rapid development and refinement of antiviral and anticancer small-molecule candidates toward preclinical evaluation.

3. Bivalent Drug Platforms, Linker Engineering, and Chemoselective Coupling Strategies

We design next-generation therapeutic modalities centered on bivalent and multivalent ligand platforms, enabling simultaneous or synergistic target engagement.
Our research includes:

- Linker strategies applicable to PROTACs, molecular glues, and ADCs

- Development of modular, chemoselective coupling units such as SuFEx-based hubs

- Construction of multifunctional chemical biology tools for probing and modulating complex biological systems

Through these platform-building efforts, we aim to expand the chemical and mechanistic diversity available for modern small-molecule therapeutics.